विधियों की तुलना करें

	प्रैग्मैटिक फेज़ II क्लिनिकल ट्रायल	चरण II नैदानिक परीक्षण
क्षेत्र	महामारी विज्ञान	महामारी विज्ञान
परिवार	Process / pipeline	Process / pipeline
उद्भव वर्ष	Pragmatic framework: 1967; Phase II application: 1990s–2000s	1960s–1970s (formalised in US federal drug regulation)
प्रवर्तक	Conceptual basis: Daniel Schwartz & Joseph Lellouch (pragmatic vs. explanatory distinction, 1967); applied to Phase II context by drug developers and trialists from the 1990s onward	U.S. Food and Drug Administration / ICH E8 guidelines (institutionalised framework)
प्रकार	Interventional study design	Interventional clinical study design
मौलिक स्रोत	Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648.	Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185392
उपनाम	pragmatic Phase II trial, real-world Phase II trial, Phase II pragmatic RCT, Phase IIb pragmatic trial	Phase 2 trial, Phase II study, early efficacy trial, proof-of-concept trial
संबंधित	6	6
सारांश	A pragmatic Phase II clinical trial is an early-to-mid-stage interventional study that evaluates a new treatment's preliminary efficacy and safety under conditions that approximate real-world clinical practice rather than tightly controlled experimental settings. It sits between pure explanatory Phase II trials and large pragmatic Phase III confirmatory trials, prioritising practical feasibility and clinical relevance while still generating the signal needed to justify further development.	A Phase II clinical trial is the second stage in the drug or intervention development pipeline, conducted after Phase I safety testing. Its primary goal is to assess whether the intervention shows preliminary efficacy signals in a relevant patient population at the dose established in Phase I, while continuing to characterise the safety and tolerability profile. Phase II trials are generally smaller than Phase III confirmatory trials and serve as critical go/no-go decision points before large-scale investment.